Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $41.20.

Several equities research analysts have issued reports on KYMR shares. Wolfe Research started coverage on shares of Kymera Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. JPMorgan Chase & Co. raised their price objective on Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Bank of America cut Kymera Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $45.00 to $30.00 in a report on Wednesday, January 3rd. Oppenheimer assumed coverage on Kymera Therapeutics in a research note on Monday. They set an “outperform” rating and a $53.00 price target on the stock. Finally, Stifel Nicolaus increased their target price on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, February 23rd.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $34.35 on Tuesday. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $45.31. The firm has a market capitalization of $2.10 billion, a P/E ratio of -13.63 and a beta of 2.27. The company’s 50-day moving average is $39.12 and its 200 day moving average is $28.18.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.19. The business had revenue of $47.90 million for the quarter, compared to analyst estimates of $41.94 million. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The business’s revenue was up 197.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.60) earnings per share. Research analysts anticipate that Kymera Therapeutics will post -3.13 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In related news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the completion of the transaction, the insider now directly owns 4,925,812 shares in the company, valued at $211,071,044.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Kymera Therapeutics news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the transaction, the insider now directly owns 4,925,812 shares of the company’s stock, valued at $211,071,044.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Bruce Booth sold 139,255 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $42.23, for a total transaction of $5,880,738.65. Following the completion of the transaction, the director now directly owns 828,830 shares in the company, valued at $35,001,490.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 474,051 shares of company stock worth $19,624,211. Insiders own 16.67% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in Kymera Therapeutics by 2.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,940 shares of the company’s stock worth $584,000 after purchasing an additional 524 shares in the last quarter. Congress Asset Management Co. MA boosted its stake in Kymera Therapeutics by 1.2% during the first quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock worth $1,843,000 after buying an additional 533 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Kymera Therapeutics by 33.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,183 shares of the company’s stock valued at $72,000 after buying an additional 1,310 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Kymera Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock worth $187,000 after acquiring an additional 1,866 shares during the last quarter. Finally, Raymond James & Associates raised its holdings in shares of Kymera Therapeutics by 7.7% during the 3rd quarter. Raymond James & Associates now owns 26,297 shares of the company’s stock worth $366,000 after acquiring an additional 1,888 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.